№ files_lp_3_process_7_056385
File format: docx
Character count: 34416
File size: 912 KB
This document outlines the guidelines for healthcare professionals on administering the Respiratory Syncytial Virus (RSV) vaccine (Abrysvo▼®) to older adults as part of the 2024 vaccination programme.
Year:
2024
Region / city:
Wales
Theme:
Health, Vaccination
Document type:
Patient Group Direction (PGD)
Organization:
Welsh Medicines Advice Service
Author:
Liam Taylor, Dianne Burnett, Hawys Youlden
Target audience:
Registered healthcare professionals
Period of validity:
01 September 2024 – 31 August 2025
Approval date:
18 July 2024
Amendment date:
28 June 2024
Expiry date:
31 August 2025
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Type of document:
Official information for health professionals
Topic:
Respiratory syncytial virus vaccination in pregnancy
Vaccine name:
Abrysvo®
Target population:
Pregnant women
Gestational age for administration:
28–36 weeks of pregnancy
Country:
Australia
Health program:
National Immunisation Program
Availability under NIP:
From 3 February 2025
Notifiable disease status:
RSV notifiable in Victoria since 22 February 2022
Regulatory authority:
Therapeutic Goods Administration
Monitoring scheme:
Black Triangle Scheme
Related legislation:
Public Health and Wellbeing Act 2008
Intended audience:
Health professionals
Storage requirements:
+2°C to +8°C
Year:
2025
Country:
Australia
Region / City:
Victoria, Melbourne
Subject:
Respiratory syncytial virus immunisation during pregnancy
Document type:
Official guidance / fact sheet
Program:
Respiratory Syncytial Virus Mother and Infant Protection Program (RSV-MIPP)
Vaccine name:
Abrysvo® RSV vaccine
Target group:
Pregnant women at 28–36 weeks gestation
Intended users:
Immunisation providers
Dose and route:
Single 0.5 mL dose, intramuscular injection into the deltoid muscle
Co-administration:
Pertussis, influenza and COVID-19 vaccines
Storage conditions:
+2°C to +8°C prior to reconstitution
Issuing authority:
Victorian Government, Department of Health
Publisher address:
1 Treasury Place, Melbourne
Publication date:
January 2025
ISBN:
978-1-76131-797-2
Copyright holder:
State of Victoria, Australia
Year:
2025
Country:
Australia
Region / City:
Victoria, Melbourne
Subject:
Respiratory syncytial virus immunisation during pregnancy
Document type:
Official guidance / fact sheet
Program:
Respiratory Syncytial Virus Mother and Infant Protection Program (RSV-MIPP)
Vaccine name:
Abrysvo® RSV vaccine
Target group:
Pregnant women at 28–36 weeks gestation
Intended users:
Immunisation providers
Dose and route:
Single 0.5 mL dose, intramuscular injection into the deltoid muscle
Co-administration:
Pertussis, influenza and COVID-19 vaccines
Storage conditions:
+2°C to +8°C prior to reconstitution
Issuing authority:
Victorian Government, Department of Health
Publisher address:
1 Treasury Place, Melbourne
Publication date:
January 2025
ISBN:
978-1-76131-797-2
Copyright holder:
State of Victoria, Australia
Year:
2024
Region / City:
Australia
Topic:
Vaccine Approval, Respiratory Syncytial Virus
Document Type:
Clinical Submission
Organization / Institution:
GlaxoSmithKline Australia Pty Ltd
Author:
Unknown
Target Audience:
Health professionals, Policy makers
Effective Period:
Ongoing
Approval Date:
January 14, 2024
Change Date:
April 2024
Year:
2024
Region / city:
England
Subject:
Respiratory Syncytial Virus (RSV) Vaccination
Document type:
Patient Group Direction (PGD)
Organization:
UK Health Security Agency (UKHSA)
Author:
Christina Wilson, Dr. Mary Ramsay, Greta Hayward
Target audience:
Healthcare practitioners, immunisation services
Valid from:
1 September 2024
Review date:
1 October 2026
Expiry date:
1 April 2027
Year:
2025
Region / City:
Victoria, Australia
Topic:
Immunisation, Respiratory Syncytial Virus (RSV)
Document type:
Consent form, Health guidance
Organization / Institution:
Victorian Government, Department of Health
Author:
Department of Health, Victoria
Target audience:
Parents/guardians of infants, Health professionals
Period of validity:
Ongoing
Date of approval:
April 2025
Date of changes:
Not specified
Year:
2024
Organization:
Department of Veterans Affairs
Office:
Office of Information Technology
Document Type:
Installation Guide
Target Audience:
VA healthcare staff
Clinical Focus:
Respiratory Syncytial Virus Immunization
Components:
Reminder Exchange entry, TIU Template, Health Summary Objects
Population:
Veterans aged 60 and above, pregnant individuals 32–36 weeks gestation
Vaccine Details:
RSV Recombinant Protein Subunit, PF, 0.5 mL
Distribution Method:
Web host file
Installation Duration:
< 20 minutes
Update Number:
2.0.394A
Effective Period:
Seasonal immunization September–January for pregnancy cohort
Year:
2026
Region / City:
Tacoma, WA, USA
Topic:
Communicable diseases in children
Document Type:
Informational letter
Organization:
Tacoma-Pierce County Health Department
Author:
Communicable Disease Division
Target Audience:
Parents and guardians of children
Symptoms:
Cold-like symptoms, bronchiolitis, pneumonia, irritability, poor feeding, lethargy, cyanosis
Transmission:
Close contact with secretions, contaminated surfaces
Prevention Measures:
Hand washing, covering coughs and sneezes, ventilating home, sanitizing surfaces
Exclusion Guidelines:
Children not required to stay home unless too sick
Contact Information:
(253) 798-6410
Type of document:
Official information for health professionals
Topic:
Respiratory syncytial virus vaccination in pregnancy
Vaccine name:
Abrysvo®
Target population:
Pregnant women
Gestational age for administration:
28–36 weeks of pregnancy
Country:
Australia
Health program:
National Immunisation Program
Availability under NIP:
From 3 February 2025
Notifiable disease status:
RSV notifiable in Victoria since 22 February 2022
Regulatory authority:
Therapeutic Goods Administration
Monitoring scheme:
Black Triangle Scheme
Related legislation:
Public Health and Wellbeing Act 2008
Intended audience:
Health professionals
Storage requirements:
+2°C to +8°C
Year:
2025
Country:
Australia
Region / City:
Victoria, Melbourne
Subject:
Respiratory syncytial virus immunisation during pregnancy
Document type:
Official guidance / fact sheet
Program:
Respiratory Syncytial Virus Mother and Infant Protection Program (RSV-MIPP)
Vaccine name:
Abrysvo® RSV vaccine
Target group:
Pregnant women at 28–36 weeks gestation
Intended users:
Immunisation providers
Dose and route:
Single 0.5 mL dose, intramuscular injection into the deltoid muscle
Co-administration:
Pertussis, influenza and COVID-19 vaccines
Storage conditions:
+2°C to +8°C prior to reconstitution
Issuing authority:
Victorian Government, Department of Health
Publisher address:
1 Treasury Place, Melbourne
Publication date:
January 2025
ISBN:
978-1-76131-797-2
Copyright holder:
State of Victoria, Australia
Year:
2025
Region / City:
Victoria, Australia
Topic:
Respiratory Syncytial Virus (RSV) Immunisation
Document Type:
Informational Leaflet
Organ / Institution:
Victorian Government, Department of Health
Author:
Victorian Government
Target Audience:
Parents and carers of infants and young children
Period of Action:
1 April 2025 to 30 September 2025
Approval Date:
February 2025
Date of Changes:
February 2025
Contextual Description:
A government-issued informational leaflet detailing RSV, its risks to infants, and the nirsevimab immunisation, including eligibility, administration, and availability.
Year:
2024
Region / city:
England
Subject:
Respiratory Syncytial Virus (RSV) Vaccination
Document type:
Patient Group Direction (PGD)
Organization:
UK Health Security Agency (UKHSA)
Author:
Christina Wilson, Dr. Mary Ramsay, Greta Hayward
Target audience:
Healthcare practitioners, immunisation services
Valid from:
1 September 2024
Review date:
1 October 2026
Expiry date:
1 April 2027
Avoiding a Serious RSV Infection and Hospitalization of Your Baby (RSV Season from October 1st 2025)
Country:
Belgium
Topic:
Prevention of RSV infection and bronchiolitis in infants
Document type:
Public health information leaflet
Target audience:
Parents of newborns and infants
Medical focus:
RSV (Respiratory Syncytial Virus) and bronchiolitis
Preventive product:
Nirsevimab (Beyfortus®)
Related vaccine:
Abrysvo®
Institutions mentioned:
Kind&Gezin; ONE in Wallonia
Period concerned:
RSV season (autumn and winter months)
Start date of measure:
October 1st 2025
Reimbursement conditions:
Social insurance with doctor’s prescription; preferential reimbursement available
Administration setting:
Maternity ward or shortly after birth
Geographical scope:
Belgium
Year:
2025
Region / City:
Victoria, Australia
Topic:
Immunisation, Respiratory Syncytial Virus (RSV)
Document type:
Consent form, Health guidance
Organization / Institution:
Victorian Government, Department of Health
Author:
Department of Health, Victoria
Target audience:
Parents/guardians of infants, Health professionals
Period of validity:
Ongoing
Date of approval:
April 2025
Date of changes:
Not specified
Year:
2015
Region / city:
Global
Topic:
Infectious diseases, sepsis, viral and bacterial co-infections
Document type:
Scientific article
Organization / institution:
Various medical institutions and researchers
Author:
Multiple authors
Target audience:
Medical professionals, researchers in infectious diseases
Effective period:
N/A
Approval date:
2015
Modification date:
N/A
Year:
2026
Region / City:
Tacoma, WA, USA
Topic:
Communicable diseases in children
Document Type:
Informational letter
Organization:
Tacoma-Pierce County Health Department
Author:
Communicable Disease Division
Target Audience:
Parents and guardians of children
Symptoms:
Cold-like symptoms, bronchiolitis, pneumonia, irritability, poor feeding, lethargy, cyanosis
Transmission:
Close contact with secretions, contaminated surfaces
Prevention Measures:
Hand washing, covering coughs and sneezes, ventilating home, sanitizing surfaces
Exclusion Guidelines:
Children not required to stay home unless too sick
Contact Information:
(253) 798-6410